RecruitingPhase 2NCT07287189

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

Studying Duchenne muscular dystrophy

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Satellos Bioscience, Inc.
Principal Investigator: Satellos Chief Medical Officer
Satellos Bioscience, Inc.
Intervention: SAT-3247(drug)
Enrollment: 51 enrolled
Eligibility: 7-9 years · MALE
Timeline: 2025 – 2027

Study locations (18)

University of California Los Angeles, Los Angeles, California, United States
Colorado Children's, Aurora, Colorado, United States
Lurie Children's, Chicago, Illinois, United States
University of Kansas, Kansas City, Kansas, United States
Kennedy Krieger Institute, Baltimore, Maryland, United States
UMass Memorial Medical Center, Worcester, Massachusetts, United States
Washington University, St Louis, Missouri, United States
Nationwide Children's Hospital, Columbus, Ohio, United States
University of Texas Southwestern, Dallas, Texas, United States
Virginia Commonwealth University, Richmond, Virginia, United States
Seattle Children's, Seattle, Washington, United States
Children's Hospital at Westmead, Westmead, New South Wales, Australia
Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia
Children's Hospital Eastern Ontario, Ottawa, Ontario, Canada
Clinic of Neurology and Psychiatry for Children and Youth, Belgrade, Serbia
+3 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07287189 on ClinicalTrials.gov

Other trials for Duchenne muscular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Duchenne muscular dystrophy →

← Back to all trials